Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 79

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 79
---
 or suits.

Third parties may assert infringement
or misappropriation claims against us with respect to our current or future products. We are aware of numerous patents issued to third
parties that may relate to aspects of our business, including the design and manufacture of CGM sensors and membranes, as well as methods
for oxygen and continuous glucose monitoring. Whether a product infringes a patent involves complex legal and factual issues, the determination
of which is often uncertain. Therefore, we cannot be certain that we have not infringed the intellectual property rights of such third
parties or others. Our competitors may assert that our systems or the methods we employ in the use of our systems are covered by U.S. or
foreign patents held by them. This risk is exacerbated by the fact that there are numerous issued patents and pending patent applications
relating to our systems in the medical technology field. Because patent applications may take years to issue, there may be applications
now pending of which we are unaware that may later result in issued patents that our products infringe. There could also be existing patents
of which we are unaware that one or more components of our system may inadvertently infringe. As the number of competitors in the market
grows, the possibility of patent infringement by us or a patent infringement claim against us increases. If we are unable to successfully
defend any such claims as they may arise or enter into or extend settlement and license agreements on acceptable terms or at all, our
business operations may be harmed.

Any infringement or misappropriation
claim could place significant strain on our financial resources, divert management’s attention from our business and harm our reputation.
In addition, if the relevant patents are upheld as valid and enforceable and we are found to infringe such patents, we could be prohibited
from selling any of our products that is found to infringe unless we could obtain licenses to use the technology covered by the patent
or are able to design around the patent. We may be unable to obtain a license on terms acceptable to us, if at all, and we may not be
able to redesign our products to avoid infringement. We may be unable to maintain or renew licenses on terms acceptable to us, if at all,
and we may be prohibited from selling any of our products that required the technology covered by the relevant licensed patents. Even
if we are able to redesign our products to avoid an infringement claim, we may not receive FDA approval for such changes in a timely manner
or at all.

Any adverse determination in